Abstract
The article presents an overview of the current problem of comorbidity of schizophrenia and type 2 diabetes mellitus, the diseases that considerably limit the quality of life of patients and cause significant difficulties in patient management. We seek to clarify the current understanding of the factors contributing to the coexistence of these diseases, highlighting the potential role of genetic, epigenetic, and environmental factors in this regard. Particular attention is paid to the effect of antipsychotic drugs on glucose metabolism and the development of insulin resistance, which may contribute to the development of type 2 diabetes in patients with schizophrenia. Data from the most relevant studies on this issue are presented, and possible strategies for managing patients with these conditions are discussed. The purpose of this article is not only to collect and systematize the existing information on the comorbidity of schizophrenia and type 2 diabetes, but also to stimulate further research in this area to develop effective approaches to the diagnosis, treatment, and management of patients with these comorbid pathologies.
Publisher
PANORAMA Publishing House
Reference7 articles.
1. 1. Yang, W.-W., Zhang, J.-W., Chen, L.-L., Fu, J.-Y., Zhu, J.-Y., & Wang, Y.-B. (2019). People with schizophrenia have a 2-5 times higher risk of developing type 2 diabetes than the general population. PubMed. Available at: https://pubmed.ncbi.nlm.nih.gov/31555784/
2. Hyperglycemia and diabetes in patients with schizophrenia or schizoaffective disorders;Cohen;PubMed Available at https//pubmed,2006
3. 3. Varnakova T.V., Artemieva M. S., Shinko S. Iu. Analiz kachestva zhizni patsientov s sochetannym techeniem shizofrenii i sakharnogo diabeta [Analysis of the quality of life of patients with combined course of schizophrenia and diabetes mellitus]. / Tekhnologii zhivykh sistem [Technologies of Living Systems]. Vol. 9, No. 7, 2012, p. 33-36. issn 2070-0997 Available at http://www.radiotec.ru. (In Russ.)
4. 4. Vestri, H. S., Maianu, L., Moellering, D. R., & Garvey, W. T. (2006). Atypical antipsychotic drugs directly impair insulin action in adipocytes: effects on glucose transport, lipogenesis, and antilipolysis. PubMed. Available at: https://pubmed.ncbi.nlm.nih.gov/16823387/
5. 5. Shinozaki, K. (2015). An Overview of Diabetes Management in Schizophrenia Patients: Office Based Strategies for Primary Care Practitioners and Endocrinologists. Hindawi. Available at: https://www.hindawi.com/journals/ije/2015/969182/